Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-0337 in Patients With Advanced Solid Tumors
NCT03416816Phase 1Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- May 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DSP-0337 in solid tumor (advanced stage), sponsored by Sumitomo Pharma America. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Recommended Phase 2 Dose at 4 weeks. Started May 2018; status: terminated.
02
Drugs
DSP-0337
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03416816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03416816.